FOSUN HEALTH Logo

Liver Cancer Diagnosis

catalogue

Liver Cancer Diagnosis

Liver Cancer Diagnosis

Liver cancer diagnosis is imaging-first, combined with a score of how well the liver is working — because in this disease the two answers carry equal weight.

Surveillance: how the disease is meant to be found

For anyone with cirrhosis, chronic hepatitis B or chronic hepatitis C, the standard is a liver ultrasound plus an AFP blood test every six months. This is not a general health check; it is a targeted programme for a group whose annual risk of liver cancer is high enough that regular scanning is worth it.

Surveillance works because liver cancers grow from a liver that is already being watched, which means many are found at a stage where removal or ablation is possible — often a year or more before any symptom would have appeared. Two practical points decide whether it delivers: the interval, which should not drift, and the quality of the imaging. Ultrasound is the usual first test worldwide because it is quick, harmless and inexpensive; it is less reliable in a very scarred liver or in a patient with a large body habitus.

If your ultrasound is technically limited, or if your AFP is rising without a clear cause, the next step is not to wait another six months — it is contrast imaging. The eligibility criteria and intervals are set out in prevention and surveillance.

Multiphase contrast CT or MRI: the central test

When surveillance or a symptom raises suspicion, the diagnostic test is a contrast-enhanced scan of the liver taken in several phases — before contrast, during the arterial phase, in the portal-venous phase and later. The reason is biological: a liver cancer develops its own arterial blood supply, so it brightens early when contrast arrives and then fades while the surrounding liver brightens. That signature — early enhancement with washout — is what identifies the tumour.

Why the phases matter

A single-phase scan can miss the diagnosis entirely. The arterial phase shows the tumour's own blood supply; the venous and delayed phases show whether it washes out and whether the portal vein is involved. Both halves of the pattern are needed before a finding is called typical.

CT or MRI?

Both are used. MRI gives better contrast between tumour and liver tissue and can characterise small or atypical lesions that CT leaves uncertain; it is also better at showing tumour inside the portal vein. CT is faster and remains the commonest first-line study. If one is inconclusive, the other is often the answer.

Findings are reported using a standardised category system (LI-RADS), which grades each lesion from definitely benign to definitely cancer based on its enhancement pattern and size. The category determines whether treatment can proceed, whether closer follow-up is needed, or whether tissue must be obtained. It also gives you and your doctors a common language: a category of 5 in an at-risk liver is treated as cancer, while a category of 3 means watch and repeat.

What to bring to any second opinion. The images themselves, in DICOM format on a disc or as a secure upload — not the printed report alone. The enhancement pattern is the evidence, and it can only be assessed from the original scan.

Blood tests: markers and liver function together

Blood testing in liver cancer has two jobs, and they are equally important.

Tumour markers

AFP is the best known and is used both in surveillance and in follow-up. PIVKA-II (also called DCP) is a second marker that can be raised when AFP is not, which is why the two are often measured together. Neither is a diagnosis on its own: markers rise and fall for many reasons and are interpreted with imaging.

Liver function

Albumin, bilirubin, clotting time, platelets and the presence of ascites or encephalopathy are combined into the Child-Pugh score, and more recently into the ALBI grade. These describe how much working liver remains — the single strongest influence on what treatment is safe to offer.

Underlying liver disease

Hepatitis B and C serology with viral load, and an assessment of how long-standing the liver disease is. This is not background detail: it determines whether antiviral treatment should start now, and it affects how treatment will be tolerated.

Read together, these results often change the plan more than the tumour measurement does. A tumour that could technically be removed may be better treated by ablation if the liver's reserve is borderline; a patient with preserved function may be able to tolerate a more ambitious approach. That judgement is the reason the panel includes hepatology as well as oncology.

When a biopsy is needed — and when it is not

In a patient with cirrhosis whose scan shows a lesion with the typical enhancement pattern, guidelines allow the diagnosis to be made without a needle. This is deliberate: a biopsy carries a small risk of bleeding and of tumour seeding along the needle track, in a liver that often has abnormal clotting. Avoiding an unnecessary invasive test is the safer choice.

Tissue is obtained when it will actually change management — for example when the imaging pattern is atypical, when the underlying liver disease is absent or uncertain, when bile-duct cancer is suspected, or when a result such as a targetable alteration or an immune marker is needed to choose a drug. A biopsy is also occasionally needed to confirm a suspected recurrence or a second primary tumour. When it is done, it is image-guided and performed with the clotting status corrected beforehand.

Staging: how the picture is completed

Staging establishes whether the tumour is confined to the liver, whether it has entered the portal vein or hepatic veins, and whether it has spread beyond the liver. Alongside the liver images, this usually means a CT of the chest and assessment for bone involvement when symptoms suggest it; PET-CT is used selectively rather than routinely, because hepatocellular carcinoma is not always PET-avid.

The result is expressed in the systems that guide treatment — the BCLC classification internationally, and the Chinese national staging system, which is widely used in practice here. Both combine the tumour, the liver and the patient's general condition, because a plan that ignores any one of the three will be wrong. Once staging is complete, the multidisciplinary panel issues one unified recommendation rather than a menu of departmental opinions: see the treatment guide for what each stage usually means in practice.

Preparing for a review from abroad

For international patients, the work-up can largely be assembled before travelling — and the more complete the file, the more definite the answer.

For international patients, send these so the panel can start:
  • Digital imaging — multiphase contrast CT or MRI of the liver in DICOM format, plus any earlier studies for comparison and chest imaging if available
  • Blood results — AFP and PIVKA-II, liver function tests including albumin and bilirubin, clotting studies, full blood count, and hepatitis B and C serology with viral load
  • Pathology and molecular reports — any biopsy report, and any molecular or immune-marker testing already performed, including FGFR2 and IDH1 results if bile-duct cancer is suspected
  • Treatment history — a short timeline of what has been done, the drugs and doses used, the response, and any side effects that led to a change
  • Current medication list — including antivirals, diuretics, blood thinners and any herbal product, since several common supplements interact with liver drugs or are themselves toxic to a damaged liver
Within 48 hours of complete records, the liver cancer panel — hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, hepatology, radiology and pathology — returns a written assessment of the stage, the treatment options that apply to you, and an indicative timeline.

Frequently Asked Questions

Can liver cancer be diagnosed without a biopsy?

Yes, in a well-defined situation: when a patient with cirrhosis or chronic hepatitis B has a lesion showing the characteristic enhancement pattern on multiphase contrast imaging, guidelines permit the diagnosis to be made from imaging alone. Avoiding the needle is intentional, because biopsy carries a small bleeding risk and a small risk of seeding tumour along the track. A biopsy is performed when imaging is atypical or when tissue is needed to choose a drug.

What does LI-RADS mean on my scan report?

LI-RADS is a standardised way of reporting liver lesions on contrast imaging in people at risk. Each lesion is assigned a category from LR-1 (definitely benign) to LR-5 (definitely cancer), based mainly on how it enhances and washes out and how large it is. A category of 5 in an at-risk liver is treated as hepatocellular carcinoma; intermediate categories mean the scan is repeated sooner or a different imaging method is used.

How long does the diagnostic work-up take?

Much of it can be done in a few days once the images and blood tests exist, because the diagnosis rests on imaging and markers rather than on waiting for tissue. Where a biopsy or additional molecular testing is required, add roughly one to two weeks. If you are coming from abroad, the panel can review records in advance and confirm exactly which extra tests are genuinely necessary during your visit.

Which blood tests matter most?

In practice two groups. The tumour markers AFP and PIVKA-II support the diagnosis and later track response, though neither is diagnostic on its own. The liver function panel — albumin, bilirubin, clotting time and platelet count — matters just as much, because it determines how much treatment the liver can tolerate. A plan based on tumour size alone, without a function score, is incomplete.

Patient Stories

Stories from our liver cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Send your imaging, get a written assessment

Upload your multiphase CT or MRI in DICOM format, your AFP and liver function results, and any pathology report. Our liver cancer panel will confirm the stage and set out the treatment options that apply to you — within 48 hours of complete records.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*